Description

Zeuzem et al. (2006) Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol, 44, 97-103.

**Zeuzem et al. (2006) Efficacy of 24 weeks treatment with peginterferon alfa‑2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol, 44, 97‑103.**

—

### A Landmark Study That Changed the Hepatitis C Treatment Landscape

When chronic hepatitis C (HCV) first entered the spotlight of modern hepatology, clinicians faced a daunting challenge: how to achieve sustained virologic response (SVR) in patients infected with the notoriously hard‑to‑treat genotype 1. The 2006 publication by Zeuzem and colleagues provided a pivotal piece of evidence that a **shortened 24‑week regimen of peginterferon alfa‑2b plus ribavirin** could be highly effective—*but only* in a specific subgroup: those with low pretreatment viremia.

### Why the Study Matters for Patients and Providers

– **Genotype 1 Focus** – Genotype 1 accounts for roughly 45 % of HCV infections worldwide and has historically responded less favorably to interferon‑based therapy.
– **Low Pretreatment Viremia** – Patients whose baseline viral load fell below 800,000 IU/mL were the primary candidates. This threshold became a key **predictive marker** for treatment success.
– **24‑Week Duration** – Traditional peginterferon‑ribavirin courses spanned 48 weeks, doubling the exposure to side effects and healthcare costs. Demonstrating comparable SVR rates in half the time opened the door to more patient‑friendly protocols.

### Study Design at a Glance

| Element | Details |
|———|———|
| **Population** | 138 treatment‑naïve adults with chronic hepatitis C, genotype 1, low baseline viral load |
| **Intervention** | Peginterferon alfa‑2b (1.5 µg/kg weekly) + ribavirin (1000–1200 mg/day) |
| **Duration** | 24 weeks of combination therapy, followed by 24 weeks of observation |
| **Primary Endpoint** | Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks post‑treatment |
| **Results** | SVR achieved in 71 % of participants; relapse rate below 5 % |

The authors highlighted that **adherence** and **early viral kinetics** (rapid virologic response at week 4) were strong predictors of the final outcome.

### Clinical Implications for Today’s Hepatologists

Even though direct‑acting antivirals (DAAs) have largely eclipsed interferon‑based regimens, the Zeuzem et al. study remains a reference point for several reasons:

1. **Baseline Viral Load as a Decision Tool** – Modern DAA guidelines still incorporate pretreatment viral load when tailoring therapy duration and selecting regimen combinations.
2. **Cost‑Effectiveness Insight** – In low‑resource settings where DAAs may be unavailable, a 24‑week peginterferon‑ribavirin protocol offers a viable, evidence‑based alternative.
3. **Historical Benchmark** – Understanding the evolution of HCV treatment helps clinicians appreciate the dramatic rise in cure rates—from ~50 % with interferon alone to >95 % with current DAAs.

### Patient Perspective: What This Means for Those Living with Hepatitis C

For patients diagnosed with genotype 1 and a low viral load, the study delivered a hopeful message: **a shorter, more tolerable therapy could still achieve a cure**. The reduced exposure to peginterferon’s flu‑like symptoms and ribavirin‑related anemia improved quality of life during treatment, a factor that continues to influence patient‑centered care models.

### Looking Ahead: From Interferon to All‑Oral Regimens

The Zeuzem et al. trial paved the way for **response‑guided therapy**, an approach that today informs the use of DAAs such as sofosbuvir/ledipasvir and glecaprevir/pibrentasvir. Researchers now ask: can we further shorten therapy based on ultra‑sensitive viral load monitoring? Early data suggest that **8‑week DAA courses** may be sufficient for select patients—mirroring the spirit of the 24‑week peginterferon breakthrough.

### Bottom Line

The 2006 Hepatology article remains a cornerstone in hepatitis C literature. By proving that **24 weeks of peginterferon alfa‑2b plus ribavirin** can deliver high SVR rates in genotype 1 patients with low pretreatment viremia, Zeuzem and colleagues not only improved treatment accessibility but also set a precedent for **personalized, duration‑optimized therapy**.

If you or a loved one are navigating chronic hepatitis C, discussing baseline viral load and treatment length with a hepatology specialist is essential. Even in the era of all‑oral DAAs, the principles uncovered in this landmark study—precision, patient‑focused care, and evidence‑backed regimens—remain as relevant as ever.

—

*Keywords: chronic hepatitis C, genotype 1, peginterferon alfa‑2b, ribavirin, low pretreatment viremia, sustained virologic response, SVR, hepatitis C treatment, antiviral therapy, viral load, clinical trial, liver disease, hepatitis C cure, response‑guided therapy.*